NASDAQ:PRCT PROCEPT BioRobotics (PRCT) Stock Price, News & Analysis $18.40 +0.50 (+2.79%) Closing price 04:00 PM EasternExtended Trading$18.40 +0.01 (+0.03%) As of 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About PROCEPT BioRobotics Stock (NASDAQ:PRCT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PROCEPT BioRobotics alerts:Sign Up Key Stats Today's Range$17.78▼$18.4450-Day Range$17.02▼$22.8952-Week Range$16.67▼$38.11Volume1.11 million shsAverage Volume1.53 million shsMarket Capitalization$1.05 billionP/E RatioN/ADividend YieldN/APrice Target$25.50Consensus RatingHold Company Overview PROCEPT BioRobotics Corp. is a medical technology company focused on developing and commercializing robotic and image-guided systems for urologic procedures. The company’s primary focus is benign prostatic hyperplasia (BPH), a noncancerous enlargement of the prostate that can cause urinary symptoms. PROCEPT’s flagship technology is Aquablation therapy, a minimally invasive, robotically controlled treatment that uses a high-velocity waterjet to remove prostate tissue. The therapy is delivered through the company’s AquaBeam Robotic System, which combines real-time imaging, surgical planning and robotic control to assist physicians during prostate procedures. PROCEPT has also developed the HYDROS Robotic System, an advanced platform designed to support Aquablation procedures. Founded in 2007 and headquartered in Redwood Shores, California, PROCEPT BioRobotics markets its systems primarily through hospitals and urology practices. The company serves the United States and international markets, subject to applicable regulatory clearances and commercial availability. Its common stock trades on the Nasdaq under the symbol PRCT.AI Generated. May Contain Errors. Read More PROCEPT BioRobotics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScorePRCT MarketRank™: PROCEPT BioRobotics scored higher than 70% of companies evaluated by MarketBeat, and ranked 218th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingPROCEPT BioRobotics has received a consensus rating of Hold. The company's average rating score is 2.31, and is based on 2 strong buy ratings, 3 buy ratings, 9 hold ratings, and 2 sell ratings.Upside PotentialPROCEPT BioRobotics has a consensus price target of $25.50, representing about 39.3% upside from its current price of $18.31.Amount of Analyst CoveragePROCEPT BioRobotics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about PROCEPT BioRobotics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for PROCEPT BioRobotics are expected to grow in the coming year, from ($1.67) to ($1.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PROCEPT BioRobotics is -9.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PROCEPT BioRobotics is -9.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPROCEPT BioRobotics has a P/B Ratio of 2.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about PROCEPT BioRobotics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.53% of the float of PROCEPT BioRobotics has been sold short.Short Interest Ratio / Days to CoverPROCEPT BioRobotics has a short interest ratio ("days to cover") of 5.56.Change versus previous monthShort interest in PROCEPT BioRobotics has recently increased by 2.64%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPROCEPT BioRobotics does not currently pay a dividend.Dividend GrowthPROCEPT BioRobotics does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.16 News SentimentPROCEPT BioRobotics has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for PROCEPT BioRobotics this week, compared to 9 articles on an average week.Search Interest7 people have searched for PRCT on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.MarketBeat Follows2 people have added PROCEPT BioRobotics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership3.7 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $476,464.00 in company stock, which represents 0.0454% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, PROCEPT BioRobotics insiders have bought 2,180.51% more of their company's stock than they have sold. Specifically, they have bought $498,315.00 in company stock and sold $21,851.00 in company stock.Percentage Held by Insiders4.00% of the stock of PROCEPT BioRobotics is held by insiders.Percentage Held by Institutions89.46% of the stock of PROCEPT BioRobotics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about PROCEPT BioRobotics' insider trading history. Receive PRCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PROCEPT BioRobotics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PRCT Stock News HeadlinesPROCEPT BioRobotics (PRCT) Could Be 70% Undervalued On Lawsuit And Board ChangeOctober 8 at 6:00 PM | finance.yahoo.comBarclays initiates coverage of PROCEPT BioRobotics with overweight ratingOctober 7 at 6:15 PM | msn.comSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.October 9 at 1:00 AM | Altimetry (Ad)Barclays Initiates PROCEPT BioRobotics at Overweight With $30 Price TargetOctober 7 at 1:14 PM | marketscreener.comMDoes New Director and Discounting Lawsuit Change The Bull Case For PROCEPT BioRobotics (PRCT)?October 6 at 3:00 PM | finance.yahoo.comPROCEPT BioRobotics (NASDAQ: PRCT) Investors: Securities Class Action Filed; Shareholders Should Contact Shareholders FoundationOctober 1, 2026 | prnewswire.comLAWSUIT ALERT: Investors who lost money with PROCEPT BioRobotics Corporation (NASDAQ: PRCT) shares should contact the Shareholders FoundationSeptember 30, 2026 | globenewswire.comPROCEPT BioRobotics Extends Term Loan Maturity AgreementSeptember 24, 2026 | tipranks.comSee More Headlines PRCT Stock Analysis - Frequently Asked Questions How have PRCT shares performed this year? PROCEPT BioRobotics' stock was trading at $31.46 on January 1st, 2026. Since then, PRCT stock has decreased by 41.8% and is now trading at $18.3110. How were PROCEPT BioRobotics' earnings last quarter? PROCEPT BioRobotics Corporation (NASDAQ:PRCT) released its quarterly earnings data on Tuesday, August, 4th. The company reported ($0.47) EPS for the quarter, missing analysts' consensus estimates of ($0.46) by $0.01. The firm's quarterly revenue was up 19.3% compared to the same quarter last year. Read the conference call transcript. When did PROCEPT BioRobotics IPO? PROCEPT BioRobotics (PRCT) raised $151 million in an IPO on Tuesday, September 14th 2021. The company issued 6,556,000 shares at a price of $22.00-$24.00 per share. Who are PROCEPT BioRobotics' major shareholders? Top institutional shareholders of PROCEPT BioRobotics include Versant Capital Management Inc. Insiders that own company stock include Frederic H Moll, Antal Rohit Desai, Kevin Waters, Reza Zadno, Alaleh Nouri, Morgan Colby Wood, Barry L Templin, Hisham Shiblaq and Larry L Wood. View institutional ownership trends. How do I buy shares of PROCEPT BioRobotics? Shares of PRCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of PROCEPT BioRobotics own? Based on aggregate information from My MarketBeat watchlists, some other companies that PROCEPT BioRobotics investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), Netflix (NFLX), Tesla (TSLA), NVIDIA (NVDA), SPDR Dow Jones Industrial Average ETF Trust (DIA) and Meta Platforms (META). Company Calendar Last Earnings8/04/2026Today10/09/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (18m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 PRCT's financial health is in the Red zone, according to TradeSmith. PRCT has been in this zone for over 18 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:PRCT CIK1588978 Webwww.procept-biorobotics.com Phone650-232-7200FaxN/AEmployees888Year Founded2009Price Target and Rating Average Price Target for PROCEPT BioRobotics$25.50 High Price Target$51.00 Low Price Target$19.00 Potential Upside/Downside+38.6%Consensus RatingHold Rating Score (0-4)2.31 Research Coverage16 Analysts Profitability EPS (Trailing Twelve Months)($1.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$95.57 million Net Margins-32.53% Pretax Margin-32.49% Return on Equity-30.62% Return on Assets-22.10% Debt Debt-to-Equity Ratio0.15 Current Ratio6.55 Quick Ratio5.35 Sales & Book Value Annual Sales$308.05 million Price / Sales3.42 Cash FlowN/A Price / Cash FlowN/A Book Value$6.55 per share Price / Book2.81Miscellaneous Outstanding Shares57,270,000Free Float54,983,000Market Cap$1.05 billion OptionableOptionable Beta0.92 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:PRCT) was last updated on 10/9/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PROCEPT BioRobotics Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share PROCEPT BioRobotics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
